Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
16 October 2017 - 11:00PM
Business Wire
- New Funds to Support Projects in HIV Cure
Discovery -
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the second
round of recipients of its HIV cure grants program. This new
commitment will provide $7.5 million to support five additional HIV
cure research initiatives led by top academic institutions and
focused on translational research and efficacy studies in
preclinical models.
“Finding a cure for HIV is a formidable challenge to the
scientific community. Together with our newest grant recipients,
all of whom have a record of excellence in their research, we can
take collective steps to help end this devastating epidemic,” said
William Lee, Ph.D., Executive Vice President, Research, Gilead
Sciences. “We are proud to support these leaders in HIV research
and are confident in their ability to make meaningful and
measurable contributions in this area of unmet medical need.”
The following organizations and corresponding projects will
receive grants from Gilead to help fund their activities
(Institution/Principal Investigator/Project Name):
- University of California, San
Francisco, School of Medicine, Microbiology and Immunology, Chan
Zuckerberg Biohub – Alexander Marson, M.D., Ph.D. – An Integrated
CRISPR Platform to Discover Regulators of HIV Latency in Primary
Human T Cells
- Institute of Human Genetics, French
National Center for Scientific Research (CNRS) and University of
Montpellier – Monsef Benkirane, Ph.D. – Paving the Way Towards
Elimination of HIV Persistent CD4T Cell In Vivo
- University of Massachusetts Medical
School – Abraham L. Brass, M.D., Ph.D. – A CRISPR/Cas9 Screen to
Discover HIV-1 Latency Factors
- Frederick National Laboratory for
Cancer Research, AIDS and Cancer Virus Program – Jeffrey D. Lifson,
M.D. – TLR Ligand Augmented, Tissue Homing AIDS Virus-Specific
Adoptive Cell Therapy to Target Viral Reservoirs
- Dana-Farber Cancer Institute – Joseph
G. Sodroski, M.D. – Unlocking HIV-1 Env to Deplete Viral
Reservoirs
The HIV cure grants program, initially announced in February
2016, underscores Gilead’s commitment to cure and ultimately
eradicate HIV and AIDS through its research and development and
philanthropic leadership. The first set of HIV cure grants,
totaling more than $22 million, were awarded to 12 projects in
January 2017.
For nearly 30 years, Gilead has been a leading innovator in the
field of HIV, driving advances in treatment, prevention, testing
and linkage to care, and cure research. In further efforts to end
the HIV epidemic, Gilead is conducting early-stage clinical
research to identify novel agents and strategies that could play a
role in eradicating HIV infection in the body.
Gilead’s corporate giving program aims to reduce health
disparities, provide access, advance medical education and support
local communities. In 2016, Funders Concerned About AIDS (FCAA)
recognized Gilead as the leading corporate global funder of
HIV/AIDS programs, and second overall behind the Bill & Melinda
Gates Foundation.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171016005352/en/
Gilead Sciences, Inc.InvestorsSung Lee, 650-524-7792orMediaBrent
Tippen, 650-653-9354
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024